Lancôme introduces Absolue Longevity MD, a new skincare line built around longevity science and visible skin age. The launch brings Urolithin-A, a molecule known from longevity supplements, into advanced facial care through Mitopure™ by Timeline. Lancôme frames the line around one central idea: skin age no longer depends only on the number of years lived, since biological changes influence firmness, vitality, resilience, and radiance over time.
SKINCARE
The brand places this launch within a broader shift in beauty, where ageing becomes a process that skincare can support through science, daily practice, and targeted formulas. Skin functions as the body’s most visible organ, which gives it a direct role in how people read health, energy, and ageing. Lancôme uses this idea to focus on visible biological age, looking at how cellular and tissue-level changes appear on the surface.
Absolue Longevity MD comes from Lancôme Longevity Integrative Science™, a proactive approach that studies ageing mechanisms at molecular, cellular, and tissue levels. The system uses the Longevity AI Cloud, a map of 267 biomarkers connected to nine biological markers of skin ageing. Lancôme organizes these markers through the Longevity Wheel, which divides ageing into structural, metabolic, and signaling functions. Each group reflects a different phase in the skin’s ageing path, from early internal damage to visible changes such as deeper wrinkles.
The line centers on Mitopure™ by Timeline, a patented molecule based on a 98.5 percent pure, micronized form of Urolithin-A. Timeline developed Mitopure™ as the active ingredient behind its longevity supplement, and Lancôme brings that technology into topical skincare through this new range. The ingredient targets mitochondrial health, a key function for skin energy, renewal, and resilience. As skin ages, mitochondria lose efficiency, which can contribute to visible fatigue and loss of vitality.
Lancôme structures Absolue Longevity MD through three routines: Anticipate, Intercept, and Reset. Each routine addresses a different stage of visible biological ageing and uses a specific complex with Mitopure™. The brand designs each formula to work as a complete routine for its phase, with one cream for each stage and additional serums for Intercept and Reset.
Anticipate targets skin with a visible biological age under 35. The cream focuses on early support, helping skin resist daily stressors before visible ageing signs appear. Its complex combines protective flavonoids, skin-related sugars, and amino acid derivatives.
Intercept addresses skin between 35 and 55, when cellular ageing processes accelerate and visible signs become more noticeable. The serum and cream support renewal, density, firmness, and radiance through amino acid building blocks, NAD+ precursors, skin-related sugars, and amino acid derivatives.
Reset targets skin above 55, when visible ageing signs have already formed. The serum and cream address mature skin through signal and biomimetic sugars, skin-related sugars, an NAD+ precursor, and amino acid derivatives.
The launch also introduces Cell BioPrint™, a beauty tech device developed with NanoEnTek. Using proteomics and lab-on-a-chip technology, the device analyzes five key biomarkers to reveal visible biological skin age, ageing speed, and future skincare needs. Based on that analysis, it guides users toward Anticipate, Intercept, Reset, or a combined protocol. Absolue Longevity MD also includes refillable packaging for the Intercept cream, reducing material use through its refill system.
